secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-118535
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Q3 net loss $7.5M ($0.09/share); Alport Phase 2 trial started, CF combo misses endpoints
--------------------------------------------------------------------------------

- Net loss of $7.5M vs $9.9M in prior-year quarter; R&D expense $4.9M, G&A $2.3M.
- Cash $24.6M as of Sep 30, 2022; expects funding into Q4 2023 subject to covenant compliance.
- Phase 2 Alport trial (NCT05448755) dosed first patient; topline results expected H1 2023.
- Phase 2 CF combination (ELX-02 + ivacaftor) did not meet efficacy endpoints; path forward to be determined with CF Foundation.
- ZKN-013 IND for RDEB on track for end of 2022 / early 2023; preclinical data presented for TURBO-ZM platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/0001104659-22-118535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/tm2230297d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-118535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer